You can now register patients with RA starting, or switching to, a number of new products including Olumiant (baricitinib), Kevzara (sarilumab), Rixathon (rituximab), Erelzi (etanercept) and Xeljanz (tofacitinib).
Updated eligibility table, checklist, re-registration guide and recruitment posters are in the process of being sent out to centres, so keep an eye out for this information in the post. Alongside this documents are being circulated electronically (where possible) and of course being made available on our WEBSITE.
Full details of relevant approvals for these new drugs have previously been circulated and can also be found HERE.
If you can’t find the answer to your questions about recruitment on our website please contact the office and we will do our best to help you.